Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹19,028 Cr
Revenue (TTM)
₹8,871 Cr
Net Profit (TTM)
₹-164 Cr
ROE
1.1 %
ROCE
6.6 %
P/E Ratio
--
P/B Ratio
2.4
Industry P/E
48.01
EV/EBITDA
18.9
Div. Yield
0.1 %
Debt to Equity
0.6
Book Value
₹59.7
EPS
₹-1
Face value
10
Shares outstanding
1,329,248,130
CFO
₹3,744.73 Cr
EBITDA
₹5,594.24 Cr
Net Profit
₹1,133.48 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Piramal Pharma
| -18.7 | -15.7 | -15.9 | -34.2 | 28.8 | -- | -- |
|
BSE Healthcare
| -3.0 | -2.8 | -3.0 | 4.1 | 25.1 | 15.7 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Piramal Pharma
| -33.3 | 92.2 | 24.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Piramal Pharma
|
140.0 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 |
| 2,261.5 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 665.5 | 13,282.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.1 | 2.4 | |
| 582.0 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 | |
| 845.9 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 | |
| 961.7 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 | |
| 1,461.0 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 | |
| 758.9 | 12,649.5 | 1,284.3 | 134.4 | -- | 30.7 | 94.1 | 10.4 | |
| 413.0 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 | |
| 1,202.1 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing... facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India. Read more
Incorporated
2020
Chairman
Nandini Piramal
Managing Director
--
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Piramal Pharma Ltd is ₹140.00 (NSE) and ₹140.10 (BSE) as of 19-Mar-2026 10:24 IST. Piramal Pharma Ltd has given a return of 28.83% in the last 3 years.
Since, TTM earnings of Piramal Pharma Ltd is negative, P/E ratio is not available.
The P/B ratio of Piramal Pharma Ltd is 2.40 times as on 18-Mar-2026, a 22 discount to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
326.26
|
3.69
|
|
2024
|
956.95
|
2.16
|
|
2023
|
0.00
|
1.21
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Piramal Pharma Ltd are Rs 240.95 and Rs 134.60 as of 19-Mar-2026.
Piramal Pharma Ltd has a market capitalisation of ₹ 19,028 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Piramal Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-3.12
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.